Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas

Figures

• 

  Figure 1. Response to Immune Checkpoint Inhibitors Among Patients With Cardiac Soft Tissue Sarcoma (A) Waterfall plot of best percentage change from baseline in the size of target lesions (sum of diameters). (B) Spider plots of percentage of baseline tumor size (sum of target lesion diameters) at each Response Evaluation Criteria in Solid Tumors version 1.1 assessment of cardiac soft tissue sarcoma. Black-colored dashed lines over −30% and 20% represent partial response (PR) and disease progression thresholds, respectively. A = angiosarcoma; NA = nonangiosarcoma; PD = progressive disease; SD = stable disease.

• 

  Figure 2. Survival Outcomes of Patients With CSTS Treated With Immune Checkpoint Inhibitors (A) Progression-free survival (PFS) of patients with advanced or metastatic cardiac soft tissue sarcoma (CSTS). (B) Overall survival (OS) of patients with advanced and metastatic CSTS. (C) Progression-free survival of patients with advanced and metastatic CSTS by histology. (D) Overall survival of patients with advanced and metastatic CSTS by histology.

• 

  Central Illustration. Survival Outcomes and Safety Profiles With Cardiac Soft Tissue Sarcoma Treated With Immunotherapy The illustration presents the 2 broad histologic categories (angiosarcoma and nonangiosarcoma). The Kaplan-Meier method was used to estimate the median overall survival (OS) using the log-rank test. Treatment-related adverse events (trAEs) were categorized as grade <3, grade ≥3, or none.

• 

  Figure 3. Swimmer Plot: 15 Patients With Nonangiosarcoma and 7 Patients With Angiosarcoma Comparison of progression-free survival between 1) an intrapatient control group, defined as the immediate prior non–immune checkpoint inhibitor (ICI) systemic therapy (if available) or post-ICI therapy if prior non-ICI systemic therapy was not available; and 2) the treatment group of interest (ie, ICI therapy). The goal of this swimmer plot is to characterize whether the treatment effect is due to the underlying behavior of the tumor compared with true treatment-specific efficacy. CDK4/6inh = cyclin-dependent kinase 4/6 inhibitor; CTLA-4 = cytotoxic T lymphocyte–associated antigen 4; IL = interleukin; NE = not evaluable; PD-1 = programmed cell death protein 1; PR = partial response; TKI = tyrosine kinase inhibitor; tx = therapy; other abbreviations as in Figure 1.